ORPHANS FIND A HOME Orphan drugs (OD) have been a part of the biotech industry almost from its inception. The pioneer in Orphan Drug development is Genzyme, which was acquired by Sanofi last year to take advantage of the OD business model. Orphan Drugs resulted from the Orphan Drug Act (ODA) of 1983. (Think of[…]
Pharmacyclics (4/5/13) â Ibrutinib â Expanding the Potential – Pancreatic Cancer, Combination Therapies and Recovery of Functional Immunity â Reiterate BUY UNDER 80 and TARGET PRICE OF 115. The AACR meeting begins this weekend in Washington, D.C. An overwhelming number of studies by every oncology company, both preclinical and human trials, are due to be[…]
Aastrom (3/27/13) – ASTM Restructures to Focus on Orphan Drug Indication, Lowering BUY and TARGET PRICE – Aastrom dropped a bomb premarket today when new CEO, Dominick Colangelo, announced that the company is shelving their Phase III CLI program and cutting half their workforce after completing a comprehensive strategic review. ASTM will now focus on[…]
March 15, 2013 Below is a pdf for Issue 750 of the Medical Technology Stock Letter. [gview file=”http://www.bioinvest.com/wp-content/uploads/2013/03/MTSL-750-March-15-20131.pdf” save=”1″]
There is no excerpt because this is a protected post.
March 29, 2013 Below is a pdf for Issue 751 of the Medical Technology Stock Letter. [gview file=”http://www.bioinvest.com/wp-content/uploads/2013/03/MTSL-751-March-29-2013.pdf” save=”1″]
Pharmacyclics (3/25/13) â BEAR RAID GIVES US OPPORTUNITY, PCYC BACK UNDER BUY LIMIT â Last week, Pharmacyclics shares dropped precipitously on the heels of several items â none of which were directly related to ibrutinibâs clinical trials, approval timeline and, hence, commercial potential. First, both ARIAâs Iclusig and ONXXâ Krypolis â two of the most[…]
Janssen (JNJ) Begins Ibrutinib Long-Term Extension Study. Pharmacyclicsâ partner Janssen has filed to begin a Phase 3b study, enrolling 200 patients who have participated in ibrutinib studies. This is a long-term follow-up study to give patients ibrutinib for up to 3 years, a logical trial to continue to monitor the long-term safety and efficacy of[…]
Pharmacyclics (4/10/13) âMajor Ibrutinib Competitor – ABT-199 – Still Seeing Tumor Lysis Syndrome; Richter’s Transformation Issues Completely Overblown. At the AACR, Rod Humerickhouse, M.D., Ph.D. of AbbVie presented an update on ABT-199, a Bcl-2 inhibitor, under development for hematologic malignancies similar to PCYC ibrutinib. Recall back in January, AbbVie suspended trials as two patients died from tumor lysis syndrome due (TLS) to[…]
Biotech Risk Management – An Oxymoron? With the vast majority of companies in the development stage and/or whose success is dependent on one key drug, biotechnology stocks are inherently quite volatile. Although the sector’s sizable rewards have been well documented of late, the outsized risks frankly never disappear. With many stocks trading at 52-week and/or[…]
Incyte’s stock is down this morning after disclosing that a UK patient taking Jakafi has died from a rare brain infection, progressive multifocal leukoencephalopathy (PML). It is unclear whether Jakafi caused the infection and that it is the only reported case among nearly 10,000 patients who have taken the drug. A review of the clinical[…]
March 1, 2013 BEST IN CLASS OR BUY THE CLASS II After the last MTSL Issue (#748) titled âThe New Hot Classesâ â âsuper pillsâ for hepatitis C, and small molecule inhibitors of the novel targets BTK, Pi3K, JAK and PCSK9 â the ideal sequel to that subject is âBest In Class or Buy The[…]
